Chlorcyclizine is a first-generation antihistamine being studied as a potential treatment for hepatitis C.
Chlorcyclizine is a first-generation antihistamine being studied as a potential treatment for hepatitis C. Chlorcyclizine is believed to inhibit an early stage of HCV infection, targeting viral entry into host cells. Chlorcyclizine inihbited the entry of cell culture-produced HCV with an IC50 value 2.3 nM. In human hepatoma cells and primary human hepatocytes, Chlorcyclizine showed a synergistic effect with other hepatitis C drugs such as ribavirin, interferon, telaprevir, boceprevir, sofosbuvir, daclatasvir, and cyclosporin A.
Cell chemical biology, 27(7), 780-792 (2020-05-11)
Chlorcyclizine (CCZ) is a potent hepatitis C virus (HCV) entry inhibitor, but its molecular mechanism is unknown. Here, we show that CCZ directly targets the fusion peptide of HCV E1 and interferes with the fusion process. Generation of CCZ resistance-associated
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.